Response Genetics, Inc., a life science company, engages in the research, development, marketing, and sale of pharmacogenomic tests for use in the treatment of cancer primarily in the United States, Asia, and Europe. It develops genetic tests that measure predictive factors for tumor response in tumor tissue samples. The company offers tests for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, and melanoma cancer patients’ tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, and ResponseDX: Melanoma test suites. It also intends to develop and commercialize tests for other types of cancer. In addition, the company engages in identifying genetic profiles of tumors that are responsive to a particular therapy. It serves community based oncologists, pathologists, physician offices, and hospitals, as well as pharmaceutical companies and research organizations through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Key Statistics